Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Coda Biotherapeutics Inc.
Headquarters: South San Francisco, CA, United States of America
Website: N/A
Year Founded: 2017
Status: Out of Business
BioCentury | Mar 24, 2023
Finance
Who’s gone? A snapshot of biotechs closing doors
Biotech struck by a wave of downsizing, restructuring and closures, as companies run out of options in an unforgiving market
BioCentury | Mar 9, 2023
Deals
March 8 Quick Takes: Opko’s ModeX in deal with Merck for EBV vaccine
Plus: BridgeBio parlays achondroplasia data into $150M follow-on, and updates from Biogen, Sage, Mesobalst and Coda
BioCentury | Mar 8, 2023
Management Tracks
Catalano named CSO at Capsida
Plus: Wagner to head government affairs at ElevateBio and updates from Novo Nordisk, AuraVax, MitoRx and more
BioCentury | Mar 9, 2022
Management Tracks
Oxford spinout MiroBio adds Keswani as CMO, promotes Murray to CSO
Plus updates from Centessa, Teon, AnchorDx, Pillar and more
BioCentury | Oct 23, 2021
Product Development
Gene therapy’s next class of biotechs
And the innovative technologies they’re developing
BioCentury | Sep 25, 2020
Finance
Human genetics leading the pull of investors into neuro
Human genetics and new modalities converge to lower the risk for neurology start-ups
BioCentury | Mar 27, 2020
Emerging Company Profile
Redpin debuts chemogenetic platform for neurology, raises $15.5M
Redpin aims to tamp down neuron excitability with its conditionally active ion channels
BioCentury | Feb 8, 2020
Product Development
Feb. 7 Product Development Quick Takes: Myriad tumbles on revenue miss; plus Verana, Sanofi, VIB, Coda, Blueprint
BioCentury | Nov 23, 2019
Company News
Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more
BioCentury | Nov 5, 2019
Finance
Coda’s chemogenetics convinces investors to re-up in series A extension
Coda raised $15M in a series A extension to begin testing its chemogenetic therapies in animals
Items per page:
1 - 10 of 13